Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Phase 0 of 18F FPM Using PET/CT in Patients With a Variety of Malignancies

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT01755650
Recruitment Status : Unknown
Verified December 2012 by Cooperative Research Centre for Biomedical Imaging Development.
Recruitment status was:  Recruiting
First Posted : December 24, 2012
Last Update Posted : December 24, 2012
Sponsor:
Information provided by (Responsible Party):
Cooperative Research Centre for Biomedical Imaging Development

Brief Summary:
The purpose of this study is to investigate the safety and potential effectiveness of the imaging compound 18F FPM for finding sites of malignancies.

Condition or disease Intervention/treatment Phase
Squamous Cell Carcinoma Radiation: 18F FPM Early Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 20 participants
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Diagnostic
Official Title: A Phase 0 Exploratory Microdosing Study of S-(3-18Ffluoropropyl)Homocysteine Hydrochloride; 18FFPM Using PET/CT in Patients With a Variety of Malignancies.
Study Start Date : October 2011
Estimated Primary Completion Date : January 2013
Estimated Study Completion Date : July 2013

Arm Intervention/treatment
Experimental: D-18F FPM Radiation: 18F FPM
Experimental: L-18F FPM Radiation: 18F FPM



Primary Outcome Measures :
  1. Safety of D-18F FPM and L-18F FPM administration as measured by occurrence of adverse clinical, biochemical or haematological events following 18F FPM administration [ Time Frame: Up to 28 days following 18F FPM administration (+/- 7 days) ]

Secondary Outcome Measures :
  1. Percentage of injected D-18F FPM and L-18F FPM dose in organs of interest. [ Time Frame: 10, 30, 60 and 120 minutes post 18F FPM administration ]
  2. Percentage of unmetabolized D-18F FPM and L-18F FPM in plasma and urine after radiotracer administration. [ Time Frame: 30 (plasma only) and 90 (plasma and urine) minutes post 18F FPM administration ]
  3. Absorbed organ doses expressed as micro Sv/MBq of administered D-18F FPM and L-18F FPM, and whole body dose expressed as milliSv/200MBq of administered dose [ Time Frame: 10, 30, 60 and 120 minutes post 18F FPM administration ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Written informed consent obtained prior to any protocol-specific procedures
  • Male and female patients with histologically confirmed squamous cell carcinoma
  • At least one site of active malignancy, as demonstrated on the pre-study 18F FDG PET/CT scan performed as part of routine clinical care
  • Age >/= 18 years
  • Life expectancy >/= 3 months
  • ECOG Performance score of 0-2

Exclusion Criteria:

  • Pregnant or breastfeeding females
  • Systemic anti-neoplastic therapy within the 2 weeks prior to the pre-study 18F FDG PET/CT scan until after the 18F FPM PET/CT scan
  • Any serious medical condition which the investigator feels may interfere with the procedures or evaluations of the study
  • Patients unwilling or unable to comply with protocol or with a history of non-compliance or inability to grant informed consent

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01755650


Contacts
Layout table for location contacts
Contact: Sonia Mailer 61 3 9467 6277 sonia.mailer@crcbid.com.au

Locations
Layout table for location information
Australia, Victoria
Peter MacCallum Cancer Centre Recruiting
East Melbourne, Victoria, Australia
Contact: Ben Solomon    61 3 9656 1111    Ben.Solomon@petermac.org   
Sponsors and Collaborators
Cooperative Research Centre for Biomedical Imaging Development
Investigators
Layout table for investigator information
Principal Investigator: Ben Solomon Peter MacCallum Cancer Centre, Australia
Layout table for additonal information
Responsible Party: Cooperative Research Centre for Biomedical Imaging Development
ClinicalTrials.gov Identifier: NCT01755650    
Other Study ID Numbers: 11/31
First Posted: December 24, 2012    Key Record Dates
Last Update Posted: December 24, 2012
Last Verified: December 2012
Keywords provided by Cooperative Research Centre for Biomedical Imaging Development:
18F FPM
PET/CT
microdosing
Additional relevant MeSH terms:
Layout table for MeSH terms
Carcinoma, Squamous Cell
Carcinoma
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Neoplasms
Neoplasms, Squamous Cell